The oral and topical formulations may have had the same results in these trials, but Ligand argues that the capsules will be easier to use for persons with large numbers of KS lesions. Oral Panretin also may be effective against KS in internal organs, although this remains to be demonstrated. Ligand plans to ask the FDA for permission to market the oral version sometime next year. Reproduced with permission. Inc. All rights reserved.
Noncommercial reproduction is encouraged.
Subscription lists are kept confidential. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only.